NIH OTT anti-cancer technologies in support of a new public-private partnership

The National Institutes of Health has launched a five-year, $215 million public-private partnership (PPP) with biopharma industry to accelerate development of immunotherapies targeted at cancer treatment. This initiative, called The Partnership for Accelerating Cancer Therapies (PACT) will be managed by the Foundation for the National Institutes of Health (FNIH) with the Food and Drug Administration serving in an advisory role.

“We have seen dramatic responses from immunotherapy, often eradicating cancer completely for some cancer patients,” said NIH Director Francis S. Collins, M.D., Ph.D.  “We need to bring that kind of success — and hope — for more people and more types of cancers, and we need to do it quickly.   A systematic approach like PACT will help us to achieve success faster.”

The PACT was setup in support of the NCI Cancer Moonshot program. The Cancer Moonshot is a program to accelerate cancer research to make more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage.

For further information on this new PPP, please visit https://www.nih.gov/news-events/news-releases/nih-partners-11-leading-bi...

For information on the NIH NCI Cancer Moonshot program visit https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative NIH OTT has numerous anti-cancer technologies available for licensing that support the above initiatives. For a complete list, visit https://www.ott.nih.gov/opportunities?field_ech2_disease_area_term_tid=77